Universitair Ziekenhuis Antwerpen
Universitair Ziekenhuis Antwerpen
Antwerp, Belgium11 results · Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer | Neoplasms by Site, Skin and Connective Tissue Diseases, breast cancer, breast disorder, breast neoplasm, neoplasm, skin disorder | Recruiting | Phase 3 | 2026-10-05 | NCT06982521 | |
| First in Human Study of CDR404 in HLA-A*02:01 Participants With MAGE-A4 Expressing Solid Tumors | Select Advanced Solid Tumors | Recruiting | Phase 1 | 2026-09-24 | NCT06402201 | |
| Continuous Monitoring of Glycemic Variability to Predict Dys- and Hyperglycemia in Asymptomatic Type 1 Diabetes | Type1 Diabetes Mellitus | Recruiting | Not applicable | 2026-08-17 | NCT05777330 | |
| AMH as a Predictor of Infertility Risk in Children With Cancer (CHANCE) | Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, neoplasm | Recruiting | Not stated | 2026-08-12 | NCT02595255 | |
| Dual-sided Hypoglossal neRvE stimulAtion for the treatMent of Obstructive Sleep Apnea (DREAM) | Apnea, Dyssomnias, Respiration Disorders, Sleep Disorders, Intrinsic, nervous system disorder, obstructive sleep apnea syndrome, respiratory system disorder, sleep apnea syndrome, sleep-wake disorder | Active, not recruiting | Not applicable | 2026-04-14 | NCT03868618 | |
| A Post-market Clinical Follow up of the Genio® System for the Treatment of Obstructive Sleep Apnea in Adults | Apnea, Dyssomnias, Respiration Disorders, Sleep Disorders, Intrinsic, nervous system disorder, obstructive sleep apnea syndrome, respiratory system disorder, sleep apnea syndrome, sleep-wake disorder | Active, not recruiting | Not applicable | 2026-03-04 | NCT04031040 | |
| Evaluating the Pharmacokinetics, Pharmacodynamics, and Safety of Efgartigimod Administered Intravenously in Children With Generalized Myasthenia Gravis | Neoplasms by Site, Paraneoplastic Syndromes, Nervous System, autoimmune disease, autoimmune disorder of the nervous system, immune system disorder, myasthenia gravis, neoplasm, nervous system disorder, neurodegenerative disease, neuromuscular disease, neuromuscular junction disease, paraneoplastic syndrome | Recruiting | Phase 2 / Phase 3 | 2026-02-18 | NCT04833894 | |
| A Study of Evorpacept (ALX148) in Patients With Advanced HER2+ Gastric Cancer (ASPEN-06) | Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Site, digestive system disorder, digestive system neoplasm, gastric adenocarcinoma, gastric cancer, gastric neoplasm, gastroesophageal junction adenocarcinoma, neoplasm, stomach disorder | Active, not recruiting | Phase 2 / Phase 3 | 2025-08-07 | NCT05002127 | |
| The Epidemiology of Suicide Attempts and Suicidal Thoughts in Flanders | Epidemiological Study; Multicenter Study; Suicidal Behavior; Suicidal Ideation; Suicide Attempt | Recruiting | Not stated | 2025-06-15 | NCT07021404 | |
| Colchicine in Belgium in Patients With Coronary Artery Disease After Percutaneous Coronary Intervention | Arterial Occlusive Diseases, arteriosclerosis disorder, cardiovascular disorder, coronary artery disorder, heart disorder, myocardial ischemia, vascular disorder | Recruiting | Phase 3 | 2024-03-08 | NCT06095765 | |
| Safety, Activity and Cell Kinetics of CYAD-211 in Patients With Relapsed or Refractory Multiple Myeloma | Blood Protein Disorders, Disease Attributes, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Recurrence, cardiovascular disorder, hematologic disorder, hemorrhagic disease, immune system disorder, immunoproliferative disorder, lymphoproliferative syndrome, monoclonal gammopathy, neoplasm, plasma cell neoplasm, vascular disorder, vascular hemostatic disease | Active, not recruiting | Phase 1 | 2023-08-31 | NCT04613557 |